Drug intelligence / Profile preview

SYP-2246

Development stage: Preclinical
Lead developer: Samyang Biopharmaceuticals
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SYP-2246 is a preclinical mRNA vaccine candidate developed by Samyang Holdings Biopharm Group for the prevention of COVID-19. The vaccine utilizes the company's proprietary SENS™ (Samyang Elucidated Nanoparticle System) platform, which is a specialized delivery technology designed to protect mRNA and facilitate its entry into cells using biodegradable polymeric nanoparticles. This delivery system is intended to overcome the stability and delivery challenges associated with mRNA therapeutics. By delivering mRNA encoding a SARS-CoV-2 antigen, SYP-2246 aims to stimulate the host's immune system to produce a protective response against the virus.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SYP-2246.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYP-2246.

Explore the full profile